Biotech | December 24, 2025
Enveda launches Phase 1 trial for first-in-class Oral IBD therapy
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Subscribe To Our Newsletter & Stay Updated
